The ruling removes a minor litigation overhang. With no financial exposure and a clean win, there is no material read-through for CME's operations or earnings. Monitor for any appeal (unlikely given the strength of the ruling).
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 30 $297.58entry
- T+1 · 8mo ago −0.75%α −3.66% · $295.35
- T+5 · 7mo ago +4.37%α +0.06% · $310.58
- T+20 · 7mo ago −4.39%α −17.00% · $284.53
- T+60 · 5mo ago −24.39%α −40.58% · $225.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CME Group won summary judgment in a former employee's discrimination and retaliation lawsuit. The court found no evidence that CME's termination decision was based on protected characteristics or retaliatory motive, and dismissed all claims with prejudice. This removes a low-probability litigation overhang with no material financial exposure.
Court Ruling Details
Key Facts
- Former employee Paul Kuscher sued CME Group for discrimination (race, national origin, gender) and retaliation under Title VII and the Illinois Human Rights Act.
- The court granted CME's motion for summary judgment on all counts, finding Kuscher failed to establish a prima facie case of discrimination or a causal link for retaliation.
- The ruling is a final judgment with prejudice, terminating the case entirely.
- No damages were awarded; the case had no disclosed settlement reserve or material financial exposure.
- The underlying allegations had been public since the case was filed in 2022, so the ruling is a confirmation event rather than a surprise.
Financial Impact
No damages awarded; case dismissed with prejudice. Legal costs were likely immaterial relative to CME's $107.7B market cap.
Risk Factors
- Plaintiff could appeal to the Seventh Circuit, though the factual record strongly supports CME and appeal prospects appear low.
- No other known related litigation against CME on similar grounds.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-o0i6c2ic-CME |
Track record
29 reports on CME
4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +17.81% at T+60 after the Mar 12, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $315.87 Now $319.37 +1.11% settles Feb 9
- Nov 9, 20267d ago 144 Neutral 1/10 Entry $304.52 Now $319.37 +4.88% settles Feb 5
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $308.27 Now $319.37 +3.60% settles Feb 2
- Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $304.06 Now $319.37 +5.04% settles Feb 1
- Nov 2, 202614d ago 3 Neutral 2/10 Entry $304.06 Now $319.37 +5.04% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $304.06 Now $319.37 +5.04% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $306.24 Now $319.37 +4.29% settles Jan 29
- Oct 27, 202620d ago Insider Cluster Neutral 2/10 Entry $294.04 Now $319.37 +8.61% settles Jan 26
- Oct 27, 202620d ago 144 Neutral 2/10 Entry $294.04 Now $319.37 +8.61% settles Jan 26
- Oct 23, 202624d ago Institutional Cluster Mixed 3/10 Entry $305.71 Now $319.37 +4.47% settles Jan 21
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers